Abstracts Archive - Page 2403 of 2607 - ACR Meeting Abstracts

Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang¹, Lang Chen³, Huifeng Yun⁴, Michael H. Schiff⁵, David Mackey⁶ and Seth Ginsberg⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Division, University of Colorado, Denver, CO, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Creaky Joints, New York, NY
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…
Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial
M. C. Genovese¹, R. F. van Vollenhoven², B. Wilkinson³, L. Wang³, S. H. Zwillich³, D. Gruben³, B. Benda⁴ and T. V. Jones⁴, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
E. B. Lee¹, J. R. Curtis², R. Riese³, C. A. Connell³, R. Chew³, M.G. Boy³, E. Maller⁴, C. Su⁴ and L. Wang³, ¹Seoul National University, Seoul, South Korea, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…
Abstract Number: 403 • 2013 ACR/ARHP Annual Meeting
Peripheral Blood Biomarkers Of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Juan Chen¹ and Dana P. Ascherman², ¹Rheumatology, The First Afflicted Hospital of Xiamen University,, Xiamen,, China, ²Medicine/Rheumatology, University of Miami, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Asymptomatic, subclinical RA-associated…
Abstract Number: 412 • 2013 ACR/ARHP Annual Meeting
Clinical Characterization Of Extensive Interstitial Lung Disease In Rheumatoid Arthritis Patients
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan

Background/Purpose: To investigate clinical characteristics of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to analyze whether high resolutional CT (HRCT) can predict…
Abstract Number: 400 • 2013 ACR/ARHP Annual Meeting
Parotid Ultrasound Abnormalities Among Rheumatoid Arthritis Patients: Prevalence and Clinical Correlates
Hong Yang¹, Doquyen H. Huynh², Arnold Ceponis³ and Arthur Kavanaugh⁴, ¹Rheumatology, UCSD, San Diego, CA, ²Rheumatology, UC San Diego School of Medicine, San Diego, CA, ³Medicine/Rheumatology, University of California San Diego, La Jolla, CA, ⁴University of California San Diego, San Diego, CA
Background/Purpose: Sjögren's syndrome (SS) occurs commonly among rheumatoid arthritis (RA) patients. It may be an indicator of, and even a contributor to, increased RA disease…
Abstract Number: 401 • 2013 ACR/ARHP Annual Meeting
Chest Pain Is Not Associated With Coronary Atherosclerosis In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Jonny Hisdal⁴, Tore K. Kvien^5,6, Anne S. Eirheim², Terje R. Pedersen⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: During cardiovascular (CV) risk stratification in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), it can be difficult to distinguish between chest pain…
Abstract Number: 402 • 2013 ACR/ARHP Annual Meeting
Can Modulators Of Inflammation Serve As Biomarkers For Subclinical Atherosclerosis In Rheumatoid Arthritis?
Kimberly P. Liang¹, Douglas P. Landsittel², Suresh R. Mulukutla³, Steven E. Reis⁴, Marc C. Levesque⁵, Donald M. Jones⁶, Rachel Gartland⁷, Ali Shoushtari⁸, Flordeliza S. Villanueva³, Hunter C. Champion⁸ and Larry W. Moreland⁵, ¹Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is independently associated with a higher risk of cardiovascular disease (CVD) and premature atherosclerosis. Mechanisms of atherosclerosis include (1) Endothelial dysfunction/activation mediated…
Abstract Number: 404 • 2013 ACR/ARHP Annual Meeting
Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis
Helga Midtbø¹, Eva Gerdts^1,2, Inge C. Olsen³, Tore K. Kvien⁴, Einar Davidsen¹ and Anne Grete Semb³, ¹Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ²Department of Cinical Science, University of Bergen, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) predisposes for increased arterial stiffness(1). In hypertension, arterial stiffness is a powerful modulator of left ventricular (LV) geometry(2). Whether this is…
Abstract Number: 405 • 2013 ACR/ARHP Annual Meeting
Gout and RA: Not Such a Rare Coexistence After All
Christina Petsch¹, Elizabeth Araujo¹, Matthias Englbrecht¹, Axel J. Hueber², Georg Schett¹, Bernhard Manger¹ and Juergen Rech², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: According to the current rheumatology literature, the simultaneous occurrence of rheumatoid arthritis (RA) and gout is rare and only a few cases have been…
Abstract Number: 406 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Case Fatality In Rheumatoid Arthritis Is Decreasing; Results From a Current Low Disease Activity Rheumatoid Arthritis Cohort and Review Of The Literature
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality. Previous studies, found increased case fatality after myocardial infarction and more frequent…
Abstract Number: 407 • 2013 ACR/ARHP Annual Meeting
Association Between Anti-Cyclic Citrullinated Peptide Antibodies Titres and The Presence and Severity Of Diffuse Interstitial Lung Disease Secondary To Rheumatoid Arthritis
Juan Manuel Ponce-Guarneros¹, Alberto Daniel Rocha Muñoz², Jorge Ivan Gámez Nava³, Soraya Amalí Zavaleta Muñíz⁴, Miriam Lizette Díaz Toscano⁵, Mario Salazar Paramo⁶, Liliana Faviola De La Cerda Trujillo⁷, Norma Guadalupe González Montoya³, Ernesto German Cardona Muñoz⁸, Monica Vazquez del Mercado⁹ and Laura González López¹⁰, ¹Medidina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social. Guadalajara., Guadalajara, Jalisco, Mexico, ²Institute for Research in Rheumatology and Musculoskeletal System, Guadalajara, Jalisco, Mexico, ³Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, ⁴Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, ⁵Fisiología, Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, ⁶Clinical Research Division, Instituto Mexicano Del SS, Guadalajara, Mexico, ⁷Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ⁸Departamento de Fisiología, Universidad de Guadalajara, Guadalajara, México, Guadalajara, Jalisco, Mexico, ⁹Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ¹⁰Medicina Interna-Reumatología, Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico
Background/Purpose: To evaluate the association between anti-cyclic citrullinated peptide antibody titres (anti-CCP) and other clinical factors with the presence and severity of Interstitial Lung Disease…
Abstract Number: 408 • 2013 ACR/ARHP Annual Meeting
Comorbidity In Early Rheumatoid Arthritis.Does Inflammation Matter ?
Lena Innala¹, Clara Sjöberg², Ewa H. Berglin³, Anna Södergren³, Bozena Möller⁴, Solbritt M. Rantapaa-Dahlqvist⁵ and Solveig Wållberg-Jonsson³, ¹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Rheumatology, Sweden, Umeå, Sweden, ²Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Department of Rheumatology, Sunderby Hospital, Luleå, Sweden, ⁵Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer from comorbidities that contribute to a shortened lifespan. The degree of inflammation is of importance for the development…
Abstract Number: 409 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lung Inflammation Evaluated With High Resolution Computed Tomography Scan Is Correlated To Rheumatoid Arthritis Disease Activity
Jorge Rojas-Serrano¹, Renzo Perez-Dorame², Heidegger Mateos-Toledo² and Mayra Mejia³, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Interstitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias Dr. Ismael Cosío Villegas. México DF., México, D.F., Mexico
Background/Purpose: To describe the association between rheumatoid arthritis disease activity (RA) and interstitial lung damage (inflammation and fibrosis), in a cohort of rheumatoid arthritis-associated interstitial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].